Most Read Articles
Stephen Padilla, 21 Jul 2017
Adherence to a beneficial lifestyle may significantly reduce the risk of chronic hypertension after hypertensive disorders of pregnancy (HDP) such as gestational hypertension and pre-eclampsia, a recent study suggests. Keeping a healthy weight appears to be critical in women with a history of HDP compared with those without such a history.
Natalia Reoutova, 4 days ago

MitraClip NTR and XTR systems are effective and well tolerated for primary mitral regurgitation (MR), as shown in the prospective, multicentre, single-arm, international, post-marketing, real-world, observational EXPAND study presented at the American College of Cardiology 2020/World Congress of Cardiology (ACC.20/WCC) virtual meeting.

Pearl Toh, Yesterday
Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.
09 Jul 2017
The Dietary Approaches to Stop Hypertension (DASH) diet is effective in reducing uric acid concentrations and risks of gout in males, a new prospective cohort study reveals. In contrast, Western diets up the risk of gout.

Ticagrelor monotherapy noninferior to DAPT plus aspirin in PCI patients

07 Nov 2019

Use of ticagrelor alone among patients who underwent percutaneous coronary intervention (PCI) after 1-month dual antiplatelet therapy (DAPT) has shown noninferiority, but is not superior, to conventional treatment in the prevention of ischaemic events, reports a study. Major bleeding is also comparable between ticagrelor monotherapy and conventional treatment.

A total of 15,991 patients undergoing PCI were randomized to 1-month DAPT followed by 23-month ticagrelor monotherapy or conventional 12-month DAPT followed by 12-month aspirin.

The authors conducted a prespecified ancillary study to assess whether experimental therapy was noninferior, and if met, superior, to conventional treatment for the coprimary efficacy endpoint of all-cause mortality, nonfatal myocardial infarction (MI), nonfatal stroke or urgent target vessel revascularization and superior in preventing BARC (Bleeding Academic Research Consortium) 3 or 5 bleeding (coprimary safety endpoint) at 2 years with a 0.025 significance level to preserve nominal 5 percent alpha error.

Investigator-reported and eventually unreported events of 7,585 patients from the 20 top-enrolling participating sites were resolved by an independent clinical event committee.

The 2-year coprimary efficacy endpoint occurred in 271 (7.14 percent) patients in the ticagrelor group and in 319 (8.41 percent) patients in the conventional group (rate ratio [RR], 95 percent confidence interval [CI], 0.72–0.99), achieving noninferiority of the former (p<0.001) but not superiority (p=0.0465). No between-group difference was seen in the rates of BARC 3 or 5 bleeding (RR, 1.00, 95 percent CI, 0.75–1.33; p=0.986).

There was a time-dependent treatment effect in the ticagrelor group, which correlated with a reduced risk of MI (RR, 0.54, 95 percent CI, 0.33–0.88; p=0.062) and definite stent thrombosis (RR, 014, 0.03–0.63; p=0.007) after 1-year post-PCI.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 21 Jul 2017
Adherence to a beneficial lifestyle may significantly reduce the risk of chronic hypertension after hypertensive disorders of pregnancy (HDP) such as gestational hypertension and pre-eclampsia, a recent study suggests. Keeping a healthy weight appears to be critical in women with a history of HDP compared with those without such a history.
Natalia Reoutova, 4 days ago

MitraClip NTR and XTR systems are effective and well tolerated for primary mitral regurgitation (MR), as shown in the prospective, multicentre, single-arm, international, post-marketing, real-world, observational EXPAND study presented at the American College of Cardiology 2020/World Congress of Cardiology (ACC.20/WCC) virtual meeting.

Pearl Toh, Yesterday
Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.
09 Jul 2017
The Dietary Approaches to Stop Hypertension (DASH) diet is effective in reducing uric acid concentrations and risks of gout in males, a new prospective cohort study reveals. In contrast, Western diets up the risk of gout.